Hsa-miR-329 exerts tumor suppressor function through down-regulation of MET in non-small cell lung cancer
Metrics: PDF 1760 views | HTML 2501 views | ?
Cheng-Cao Sun1, Shu-Jun Li1,2, Feng Zhang1, Jing-Yu Pan1, Liang Wang1, Cui-Li Yang1, Yong-Yong Xi1 and De-Jia Li1
1 Department of Occupational and Environmental Health, School of Public Health, Wuhan University, Wuhan, P. R. China
2 Wuhan Hospital for the Prevention and Treatment of Occupational Diseases, Wuhan, P. R. China
De-Jia Li, email:
Keywords: hsa-miRNA-329(miR-329); MET; non-small cell lung cancer (NSCLC); proliferation; apoptosis
Received: August 18, 2015 Accepted: February 05, 2016 Published: February 19, 2016
MicroRNAs (miRNAs) act as key regulators of multiple cancers. Hsa-miR-329 (miR-329) functions as a tumor suppressor in some malignancies. However, its role on lung cancer remains poorly understood. In this study, we investigated the role of miR-329 on the development of lung cancer. The results indicated that miR-329 was decreased in primary lung cancer tissues compared with matched adjacent normal lung tissues and very low levels were found in a non-small cell lung cancer (NSCLC) cell lines. Ectopic expression of miR-329 in lung cancer cell lines substantially repressed cell growth as evidenced by cell viability assay, colony formation assay and BrdU staining, through inhibiting cyclin D1, cyclin D2 and up-regulatiing p57(Kip2) and p21(WAF1/CIP1). In addition, miR-329 promoted NSCLC cell apoptosis, as indicated by up-regulation of key apoptosis gene cleaved caspase-3, and down-regulation of anti-apoptosis gene Bcl2. Moreover, miR-329 inhibited cellular migration and invasiveness through inhibiting matrix metalloproteinases (MMP)-7 and MMP-9. Further, oncogene MET was revealed to be a putative target of miR-329, which was inversely correlated with miR-329 expression. Furthermore, down-regulation of MET by siRNA performed similar effects to over-expression of miR-329. Collectively, our results demonstrated that miR-329 played a pivotal role in lung cancer through inhibiting cell proliferation, migration, invasion, and promoting apoptosis by targeting oncogenic MET.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.